The daratumumab DRP ® was developed by correlating gene expression patterns with sensitivity to daratumumab-induced antibody-dependent cellular cytotoxicity (ADCC), based on published in vitro ...

This novel predictor is designed to identify multiple myeloma patients most likely to benefit from daratumumab. The daratumumab DRP ® was developed by correlating gene expression patterns with ...